NCT06250257View on ClinicalTrials.gov

Bromocriptine in Dilated Cardiomyopathy Among Women of Reproductive Age

PHASE3RecruitingINTERVENTIONAL
Enrollment

112

Participants

Timeline

Start Date

October 21, 2024

Primary Completion Date

May 30, 2026

Study Completion Date

November 30, 2026

Conditions
Dilated Cardiomyopathy
Interventions
DRUG

Bromocriptine mesylate plus standard GDMT

The treatment group will receive bromocriptine 2.5mg PO daily for 8 weeks together with standard GDMT which include similar patterns of BBs, ACEI/ARBs, MRAs and SGLT2 inhibitors.

Trial Locations (1)

378

RECRUITING

Jimma Medical Center, Jimma

All Listed Sponsors
collaborator

Ludwig Maximilian university of Munich

UNKNOWN

lead

Jimma University

OTHER